Tirzepatide Wins the Weight-Loss Race, But New Data Says It Might Be Costing You More Muscle

Everyone agrees on one thing about tirzepatide: it's the "stronger" GLP-1 drug. Bigger weight loss, better numbers, obvious upgrade from semaglutide. Right?

New real-world data pumps the brakes on that idea. A preprint posted on medRxiv used body-composition "digital phenotyping", basically ongoing tracking of fat and muscle, not just total pounds, in people using tirzepatide and semaglutide in everyday clinical care. The finding: tirzepatide users lost noticeably more lean body mass than semaglutide users, not just more total weight. Important: I'm not a doctor. Everything here is based on published and preprint research, not medical advice. Talk to your physician before making any changes to your GLP-1 protocol.

The Bottom Line

• The popular belief is "tirzepatide loses more weight, so it's just better." That's true for the scale, it's not the whole story.
• A real-world body-composition study found tirzepatide users lost a greater share of lean muscle mass compared to semaglutide users, not just more fat.
• This is a preprint (not yet peer-reviewed), so treat it as an early signal, not a final verdict, but it lines up with smaller studies flagging muscle loss on both drugs.
• More total weight loss doesn't automatically mean healthier weight loss. What you lose matters as much as how much you lose.
• Actionable takeaway: if you're on tirzepatide, prioritize protein intake and resistance training more aggressively than you would on semaglutide, the muscle-loss risk appears higher, not lower.

The Popular Belief: "Tirzepatide Is Just Semaglutide, Turned Up a Notch"

The logic makes sense on paper. Tirzepatide targets two gut hormone receptors (GLP-1 and GIP) instead of one. Head-to-head trials like SURMOUNT and STEP showed people on tirzepatide lost around 20-25% of body weight, compared to roughly 15% on semaglutide.

So the assumption became: same drug class, same mechanism, tirzepatide just does it better. Many people switch from semaglutide to tirzepatide expecting a strict upgrade with no tradeoffs, you can read more about how that decision usually gets framed in our guide on switching from semaglutide to tirzepatide.

The problem is, "more weight loss" was never the same question as "more fat loss." Those two numbers get treated like they're identical. The new data suggests they're not.

What the New Study Actually Found

The medRxiv preprint used something called body-composition digital phenotyping. In plain terms, that means researchers tracked fat mass and lean mass over time using device-based measurements, not just self-reported weight, and not just a one-time DEXA scan at the start and end of a trial.

Across a routine-care population (real patients, real prescriptions, not a controlled trial), tirzepatide was associated with a greater decline in lean body mass than semaglutide, even after accounting for total weight lost.

That distinction matters. Lean mass isn't just muscle you see in the mirror. It includes skeletal muscle, organ tissue, and other metabolically active tissue that helps regulate blood sugar, strength, and how many calories you burn at rest.

This lines up with data from a separate peer-reviewed study, effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity, which also found meaningful reductions in lean mass alongside fat mass during treatment. The medRxiv preprint adds something new: it suggests the split between fat loss and muscle loss may not be the same across drugs, even within the same GLP-1 family.

Why This Should Change How You Think About "Which Drug Is Better"

Here's the contrarian part. If you've been choosing between semaglutide and tirzepatide purely by asking "which one melts more pounds," you've been asking half the question.

Weight loss is not automatically fat loss. Studies across the GLP-1 class, not just this one, have repeatedly shown that somewhere between 25% and 40% of total weight lost on these drugs can come from lean mass, not fat. We've covered this pattern in more depth in our breakdown of GLP-1 muscle loss and what the research actually shows.

If tirzepatide is pulling a larger share of that loss from muscle specifically, then a bigger number on the scale might not represent a bigger metabolic win. It could represent a bigger metabolic cost.

Muscle loss isn't cosmetic. Less lean mass means a lower resting metabolic rate, which makes weight regain more likely after stopping treatment. It also means less physical strength and reserve, especially in older adults, a concern we've written about specifically for protecting lean mass on semaglutide and Mounjaro.

So the "stronger drug wins" framing misses the point. The real question isn't which drug removes more weight. It's which drug removes the right weight.

Hold On, Is One Preprint Enough to Change Your Mind?

Fair pushback. This medRxiv paper is a preprint. That means it hasn't gone through peer review yet, and the methods and conclusions could still shift before final publication. Treat it as an early signal, not gospel.

But it's not an isolated claim. It fits a growing body of evidence:

• A cohort study on GLP-1 receptor agonists and major safety outcomes found real-world risk patterns often differ from what controlled trials show, reinforcing why routine-care data (like this digital phenotyping study) is valuable even when it's messier than a clinical trial.
• Body composition sub-studies within tirzepatide's own trial program have already flagged lean mass reduction as a recurring finding, not a fluke.
• Multiple smaller studies on semaglutide have shown similar, if somewhat smaller, muscle loss signals, this isn't a "tirzepatide is dangerous, semaglutide is safe" story. It's a "the difference in degree matters" story.

In other words, this isn't a single outlier data point contradicting a mountain of contrary evidence. It's one more piece confirming a pattern researchers have been circling for a while, with a suggestion that the pattern might be stronger with the dual-receptor drug.

What This Actually Means for You

If you're currently choosing between semaglutide and tirzepatide, or you already switched because tirzepatide "does more," here's the practical shift in thinking:

Don't pick a drug based on total weight loss alone. Ask your provider about body composition monitoring if it's available, even a basic bioelectrical impedance scale at your gym or pharmacy gives you more useful information than a bathroom scale number.

Protein and resistance training aren't optional add-ons, they're the counterweight. Research on semaglutide muscle preservation strategies and tirzepatide lean mass preservation protocols both point to the same fix: higher protein intake (often 1.2-1.6g per kg of body weight) plus regular resistance training measurably blunts the lean mass loss seen on these drugs.

If you're on tirzepatide, take the muscle-loss risk more seriously, not less. The instinct is to assume the "stronger" drug is safer because it's more effective. This data suggests the opposite might be true for body composition specifically.

Slower titration might help. Rapid weight loss, in general, tends to pull more from lean mass than gradual loss does. If your provider is comfortable with it, a slower dose increase may reduce how much muscle gets swept up in the process.

FAQ

Does this mean tirzepatide is worse than semaglutide? No. Tirzepatide still produces greater average weight loss and strong results for blood sugar control. This data suggests a tradeoff exists, not that the drug is unsafe or inferior overall.

Is this preprint peer-reviewed yet? No. It's posted on medRxiv, which hosts research before formal peer review. The findings are worth paying attention to, but they could be refined or revised once published in a journal.

How much muscle loss is "normal" on GLP-1 drugs? Estimates vary, but several studies put lean mass loss at roughly 25-40% of total weight lost, depending on the drug, dose, and whether someone is doing resistance training. Individual results vary widely.

Should I stop tirzepatide because of this? This isn't a reason to stop treatment on your own. It's a reason to bring up protein intake, strength training, and body composition tracking with your prescriber. Never adjust or stop a GLP-1 medication without talking to your doctor first.

Does semaglutide cause zero muscle loss? No, semaglutide has its own documented lean mass loss in research, just apparently to a lesser degree than what this study found for tirzepatide. Neither drug is muscle-neutral.

The Takeaway

The scale has trained all of us to think "more weight loss" automatically means "winning." This new data is a good reminder that the number going down doesn't tell you what's actually leaving your body. If you're on tirzepatide, or considering it over semaglutide, the smartest move isn't to fear the drug, it's to protect the muscle it might be taking with it. Talk to your doctor about body composition tracking, load up on protein, and don't skip the strength training just because the injection is doing the "hard work."

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research, not medical recommendations.

Sources

1. Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotyping, medRxiv preprint, 2026
2. Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity, 2026
3. GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study, Diabetes, Obesity & Metabolism, 2026
4. Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists, Diabetes, Obesity & Metabolism, 2026
5. GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology, Diabetes, Obesity & Metabolism, 2026